Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Taher Nassar

Simon Benita

Michael M Friedman

Abraham Rubinstein

Joseph Tam

Dan Gibson

Muhammad Baluom

Boaz Tirosh

Aiman Abu Ammar

Liat Kochavi-Soudry

Raphael Radai

Orit Amsalem

Shira Hirsh

The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.

CB1R receptor blockers with acyclic backbones

Provided are Pt (IV) lipophilic derivatives for improved drug performance in cancer therapy, as well as nanocarriers including the same.

Pt (IV) derivatives and nanocarriers comprising them

Provided is a nanoparticle including a water-soluble protein, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by a metaphosphate.

Nanoencapsulation of hydrophilic active compounds

The present invention makes use of a unique methodology of double nano-encapsulation for protecting and controlling the release of active agents, either hydrophobic or hydrophilic, from stable nanoparticles of opposite characteristics. The protection of the active agent was achieved by loading the agent to be protected, into nanocarriers, which were subsequently encapsulated into sub-micron nanoparticles. The sub-micron nanoparticles formation has been successfully achieved by the use of novel nano spray techniques.

Nano delivery systems for siRNA

The present invention relates to a controlled release drug delivery system comprising a drug which is susceptible to enzymatic degradation by enzymes present in the intestinal tract; and a polymeric matrix which undergoes erosion in the gastrointestinal tract comprising a hydrogel-forming polymer selected from the group consisting of (a) polymers which are themselves capable of enhancing absorption of said drug across the intestinal mucosal tissues and of inbihiting degradation of said drug by intestinal enzymes; and (b) polymers which are not themselves capable of enhancing absorption of said drug across the intestinal mucosal tissues and of inhibiting degradation of said drug by intestinal enzymes; wherein when the matrix comprises a polymer belonging to group (b) the delivery system further comprises an agent which enhances absorption of said drug across the intestinal mucosal tissues and/or an agent which inhibits degradation of said drug by intestinal enzymes and when the matrix comprises a polymer belonging to group (a) the delivery system optionally further comprises an agent which enhances absorption of said drug across the intestinal mucosal tissues and/or an agent which inhibits degradation of said drug by intestinal enzymes.

Growing community of inventors

Kfar Tur'an, Israel

Taher Nassar